Welcome to the official RUKOBIA account.
Prescribing Information: https://gsk.to/3yEZgun
Community Guidelines: https://gsk.to/4aBqlLX
Intended for US healthcare professionals only.
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
©2025 ViiV Healthcare or licensor.
PMUS-FSTSMP250002 May 2025
Produced in USA.
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://RUKOBIAHCP.com
- Keywords
- New York.
- Competitors
- DOVATO (dolutegravir/lamivudine), REXULTI® (brexpiprazole) HCP, APRETUDE (cabotegravir extended-release injectable suspension), CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), NPHub, FS Insight, TAGRISSO® (osimertinib) HCP, Entyvio (vedolizumab), Physician Side Gigs, BENLYSTA (belimumab).
Rukobia (Fostemsavir) Questions
Rukobia (Fostemsavir)'s website is http://RUKOBIAHCP.com
Rukobia (Fostemsavir)'s LinkedIn profile is https://www.linkedin.com/company/rukobiahcp
Rukobia (Fostemsavir)'s industry is
Pharmaceutical Manufacturing
Rukobia (Fostemsavir)'s top competitors are
Dovato (Dolutegravir/lamivudine),
Rexulti® (Brexpiprazole) Hcp,
Apretude (Cabotegravir Extended-Release Injectable Suspension),
Cabenuva (Cabotegravir And Rilpivirine Extended-Release Injectable Suspensions),
Nphub,
Fs Insight,
Tagrisso® (Osimertinib) Hcp,
Entyvio (Vedolizumab),
Physician Side Gigs,
Benlysta (Belimumab).
Rukobia (Fostemsavir)'s categories are Pharmaceutical Manufacturing
